1887

Abstract

Herpes simplex virus (HSV) is a ubiquitous organism that causes infections in human populations throughout the world. It causes a variety of diseases ranging in severity from mild to life-threatening. In this study, -epiafzelechin-(4→8)-epiafzelechin (EEE) extracted from the fresh leaves of L. de Wit (Leguminosae) was investigated for its anti-HSV-2 activity using XTT and plaque reduction assays. Results showed that EEE inhibited HSV-2 replication in a dose-dependent manner. The IC value was 83·8±10·9 and 166·8±12·9 μM for XTT and plaque reduction assays, respectively. EEE did not affect the viability and the proliferation of cells at antiviral concentrations. Mechanistic studies demonstrated that EEE prevented HSV-2 from penetrating the cell and also interfered with HSV-2 replication at the late stage of its life cycle. It also disturbed virus attachment but the inhibitory effect was minor. In summary, the conclusion of this study was that EEE exhibits various modes of action in suppressing HSV-2 multiplication.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.46110-0
2006-02-01
2019-11-21
Loading full text...

Full text loading...

/deliver/fulltext/jmm/55/2/201.html?itemId=/content/journal/jmm/10.1099/jmm.0.46110-0&mimeType=html&fmt=ahah

References

  1. Albin, R., Chase, R., Risano, C. & 13 other authors ( 1997; ). SCH 43478 and analogs: in vitro activity and in vivo efficacy of novel agents for herpesvirus type 2. Antiviral Res 35, 139–146.[CrossRef]
    [Google Scholar]
  2. Aurelian, L. ( 2000; ). Herpes simplex virus. In Clinical Virology Manual, pp. 384–409. Edited by S. Specter, R. L. Hodinka & S. A. Young. Washington, DC: American Society for Microbiology.
  3. Boulware, S. L., Bronstein, J. C., Nordby, E. C. & Weber, P. C. ( 2001; ). Identification and characterization of a benzothiophene inhibitor of herpes simplex virus type 1 replication which acts at the immediate early stage of infection. Antiviral Res 51, 111–125.[CrossRef]
    [Google Scholar]
  4. Brady, R. C. & Bernstein, D. I. ( 2004; ). Treatment of herpes simplex virus infections. Antiviral Res 61, 73–81.[CrossRef]
    [Google Scholar]
  5. Carlucci, M. J., Ciancia, M., Matulewicz, M. C., Cerezo, A. S. & Damonte, E. B. ( 1999; ). Antiherpetic activity and mode of action of natural carrageenans of diverse structural types. Antiviral Res 43, 93–102.[CrossRef]
    [Google Scholar]
  6. Cheng, H. Y., Lin, C. C. & Lin, T. C. ( 2002a; ). Antiherpes simplex virus type 2 activity of casuarinin from the bark of Terminalia arjuna Linn. Antiviral Res 55, 447–455.[CrossRef]
    [Google Scholar]
  7. Cheng, H. Y., Lin, C. C. & Lin, T. C. ( 2002b; ). Antiviral properties of prodelphinidin B-2 3′-O-gallate from green tea leaf. Antivir Chem Chemother 13, 223–229.[CrossRef]
    [Google Scholar]
  8. Cheng, H. Y., Lin, T. C., Ishimaru, K., Yang, C. M., Wang, K. C. & Lin, C. C. ( 2003; ). In vitro antiviral activity of prodelphinidin B-2 3, 3′-di-O-gallate from Myrica rubra. Planta Med 69, 953–956.[CrossRef]
    [Google Scholar]
  9. Cheng, H. Y., Lin, T. C., Yang, C. M., Wang, K. C., Lin, L. T. & Lin, C. C. ( 2004a; ). Putranjivain A from Euphorbia jolkini inhibits both virus entry and late stage of replication of herpes simplex virus type 2 in vitro. J Antimicrob Chemother 53, 577–583.[CrossRef]
    [Google Scholar]
  10. Cheng, H. Y., Lin, T. C., Yang, C. M., Wang, K. C. & Lin, C. C. ( 2004b; ). Mechanism of action of the suppressing of herpes simplex virus type 2 replication by pterocarnin A. Microbes Infect 6, 738–744.[CrossRef]
    [Google Scholar]
  11. Chilukuri, S. & Rosen, T. ( 2003; ). Management of acyclovir-resistant herpes simplex virus. Dermatol Clin 21, 311–320.
    [Google Scholar]
  12. Chinese Herbal Commission of the National Administrative Department on Chinese Medicine & Pharmacy ( 1999; ). Chinese Herbal. Shanghai: Shanghai Science & Technology Press.
  13. Christophers, J., Clayton, J., Craske, J., Ward, R., Collins, P., Trowbridge, M. & Darby, G. ( 1998; ). Survey of resistance of herpes simplex virus to acyclovir in northwest England. Antimicrob Agents Chemother 42, 868–872.
    [Google Scholar]
  14. Corey, L. ( 2002; ). Increasing prevalence of HSV-2 points to need for more effective prevention strategies. Herpes 9, 3.
    [Google Scholar]
  15. Danve-Szatanek, C., Aymard, M., Thouvenot, D. & 29 other authors ( 2004; ). Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol 42, 242–249.[CrossRef]
    [Google Scholar]
  16. De Clercq, E. ( 2001; ). Molecular targets for antiviral agents. J Pharmacol Exp Ther 297, 1–10.
    [Google Scholar]
  17. De Logu, A., Loy, G., Pellerano, M. L., Bonsignore, L. & Schivo, M. L. ( 2000; ). Inactivation of HSV-1 and HSV-2 and prevention of cell-to-cell virus spread by Santolina insularis essential oil. Antiviral Res 48, 177–185.[CrossRef]
    [Google Scholar]
  18. Englund, J. A., Zimmerman, M. E., Swierkosz, E. M., Goodman, J. L., Scholl, D. R. & Balfour, H. H., Jr ( 1990; ). Herpes simplex virus resistant to acyclovir: a study in a tertiary care center. Ann Intern Med 112, 416–422.[CrossRef]
    [Google Scholar]
  19. Griffiths, P. D. ( 1996; ). Herpesviruses and AIDS. Scand J Infect Dis Suppl 100, 3–7.
    [Google Scholar]
  20. Kashiwada, Y., Iizuka, H., Yoshioka, K., Chen, R. F., Nonaka, G. I. & Nishioka, I. ( 1990; ). Tannins and related compounds. XCIII. Occurrence of enantiomeric proanthocyanidins in the Leguminosae plants, Cassia fistula L. and C. javanica L. Chem Pharm Bull 38, 888–893.[CrossRef]
    [Google Scholar]
  21. Kleymann, G., Fischer, R., Betz, U. A. & 20 other authors ( 2002; ). New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat Med 8, 392–398.[CrossRef]
    [Google Scholar]
  22. Lin, C. C., Cheng, H. Y., Yang, C. M. & Lin, T. C. ( 2002; ). Antioxidant and antiviral activities of Euphorbia thymifolia L. J Biomed Sci 9, 656–665.
    [Google Scholar]
  23. Liuzzi, M., Deziel, R., Moss, N. & 11 other authors ( 1994; ). A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo. Nature 372, 695–698.[CrossRef]
    [Google Scholar]
  24. Morfin, F. & Thouvenot, D. ( 2003; ). Herpes simplex virus resistance to antiviral drugs. J Clin Virol 26, 29–37.[CrossRef]
    [Google Scholar]
  25. Naesens, L. & De Clercq, E. ( 2001; ). Recent developments in herpesvirus therapy. Herpes 8, 12–16.
    [Google Scholar]
  26. Nugier, F., Colin, J. N., Aymard, M. & Langlois, M. ( 1992; ). Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: report on a 2-year sensitivity screening survey. J Med Virol 36, 1–12.[CrossRef]
    [Google Scholar]
  27. Pillay, D., Mutimer, D., Singhal, S., Turner, A., Ward, K. & Wood, M. ( 2000; ). Management of herpes virus infections following transplantation. J Antimicrob Chemother 45, 729–748.[CrossRef]
    [Google Scholar]
  28. Rajcani, J. & Vojvodova, A. ( 1998; ). The role of herpes simplex virus glycoproteins in the virus replication cycle. Acta Virol 42, 103–118.
    [Google Scholar]
  29. Roizman, B. & Sears, A. E. ( 1996; ). Herpes simplex viruses and their replication. In Virology, 3rd edn, pp. 2231–2295. Edited by B. N. Fields, D. M. Knipe & P. M. Howley. Philadelphia: Lippincott-Raven Publishers.
  30. Smith, J. S. & Robinson, N. J. ( 2002; ). Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis 186, S3–S28.[CrossRef]
    [Google Scholar]
  31. Spear, P. G. ( 1993; ). Entry of alphaherpesviruses into cells. Semin Virol 4, 167–180.[CrossRef]
    [Google Scholar]
  32. Tal-Singer, R., Peng, C., Ponce De Leon, M., Abrams, W. R., Banfield, B. W., Tufaro, F., Cohen, G. H. & Eisenberg, R. J. ( 1995; ). Interaction of herpes simplex virus glycoprotein gC with mammalian cell surface molecules. J Virol 69, 4471–4483.
    [Google Scholar]
  33. Wathen, M. W. ( 2002; ). Non-nucleoside inhibitors of herpesviruses. Rev Med Virol 12, 167–178.[CrossRef]
    [Google Scholar]
  34. Weislow, O. S., Kiser, R., Fine, D. L., Bader, J., Shoemaker, R. H. & Boyd, M. R. ( 1989; ). New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J Natl Cancer Inst 81, 577–586.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.46110-0
Loading
/content/journal/jmm/10.1099/jmm.0.46110-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error